Rare diseases have long been under-researched, with many unaware that such conditions even existed. The global orphan drug market generated nearly $123 billion in 2014 and will continue to grow to reach nearly $191 billion by 2019.
With such growth and innovation, now is the best time to discuss the best strategist to follow. Bearing in mind, Germany is Europe’s largest pharma market and also recognised as having one of the toughest pricing policies in Europe, The 6th annual Orphan Drugs will discuss the controversial German pricing mechanism as well as bring together leading industry professionals to share the different opinions of the latest regulatory developments, exploring how to reduce costs and learn from the latest innovations in the orphan drug landscape.
Some of the speakers during both days 15th and 16th of May 2017 will be from companies as: Aegerion Pharmaceuticals, Institute of Pharmaceutical Research & Technology, Therachon AG, NovoNordisk, Orphan Europe, SYMPTOMA, Alexion Pharma GmbH, ATAXIA UK, etc.
For more information and to register online, please visit: www.orphandrugs-event.com or click on the links below:
ORPHAN DRUG´S HOME
PROGRAMME
VENUE
